<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Blood Sci</journal-id><journal-id journal-id-type="iso-abbrev">Blood Sci</journal-id><journal-id journal-id-type="pmc-domain-id">4164</journal-id><journal-id journal-id-type="pmc-domain">bloodsci</journal-id><journal-id journal-id-type="publisher-id">BS9</journal-id><journal-title-group><journal-title>Blood Science</journal-title></journal-title-group><issn pub-type="epub">2543-6368</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431758</article-id><article-id pub-id-type="pmcid-ver">PMC12431758.1</article-id><article-id pub-id-type="pmcaid">12431758</article-id><article-id pub-id-type="pmcaiid">12431758</article-id><article-id pub-id-type="doi">10.1097/BS9.0000000000000252</article-id><article-id pub-id-type="publisher-id">BLS-25-090</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Daratumumab in relapsed or refractory immune thrombocytopenic purpura</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tomuleasa</surname><given-names initials="C">Ciprian</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gale</surname><given-names initials="RP">Robert Peter</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><aff id="aff1"><label>a</label>Department of Personalized Medicine and Rare Diseases - Medfuture Institute for Biomedical Research/Department of Hematology, Iuliu Ha&#539;ieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</aff><aff id="aff2"><label>b</label>Department of Hematology, Iuliu Ha&#539;ieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</aff><aff id="aff3"><label>c</label>Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK</aff><aff id="aff4"><label>d</label>Department of Hematology, Peking University People&#8217;s Hospital, Beijing, China</aff><aff id="aff5"><label>e</label>Department of Hematology, Sun Yat-sen Cancer Centre, Guangzhou, China</aff></contrib-group><author-notes><corresp id="c1">*Address correspondence: Ciprian Tomuleasa, Department of Personalized Medicine and Rare Diseases - Medfuture Institute for Biomedical Research/Department of Hematology, Iuliu Ha&#539;ieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. E-mail address: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ciprian.tomuleasa@umfcluj.ro">ciprian.tomuleasa@umfcluj.ro</email> (C. Tomuleasa).</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>7</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">496820</issue-id><fpage>e00252</fpage><lpage>e00252</lpage><history><date date-type="received"><day>21</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College (IHCAMS).</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bs9-7-e00252.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bs9-7-e00252.pdf"/><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by autoantibody-mediated platelet destruction and impaired platelet production, leading to bleeding risk at platelet counts &lt;100 &#215; 10<sup>9</sup>/L. In adults, ITP often becomes chronic and recurrent, necessitating multiple lines of therapy, including corticosteroids, intravenous immunoglobulins, splenectomy, rituximab, thrombopoietin receptor agonists (TPO-RAs), and fostamatinib. Yet a subset of patients remains relapsed/refractory (r/r), with residual autoantibody-producing plasma cells driving persistent disease. Standard immunosuppression, as is the case of rituximab, targets CD20+ B lymphocytes and might spare long-lived plasma cells (LLPCs). Autoantibodies persist if LLPCs survive. Daratumumab binds CD38 expressed on plasmablasts and plasma cells, including LLPCs; and depletes them efficiently, removing autoantibody sources.</p><p>Two adults with primary refractory ITP, including after multiple relapses, prior therapies including steroids, rituximab and/or TPO-Ras, received off-label daratumumab. One achieved rapid and sustained platelet recovery, while the other showed stabilization. Crickx et al<sup><xref rid="R1" ref-type="bibr">1</xref></sup> described 5 cases treated with 4 to 7 weekly infusions: 2 achieved sustained responses at 3 months. Str&#252;&#223;mann et al<sup><xref rid="R2" ref-type="bibr">2</xref></sup> described a long-standing ITP patient achieving remission lasting at least 20 months. Autoimmune thrombocytopenia post-hematopoietic stem cell transplantation (HSCT) is often refractory.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Several pediatric and adult cases reported efficacy, including durable responses after daratumumab in life-threatening settings. Although distinct from primary ITP, iTTP involves autoantibodies against ADAMTS13. Daratumumab has been used to eradicate anti-ADAMTS13 autoantibodies and restore enzyme activity in relapsed cases after rituximab. Summarized reports show that daratumumab produces sustained responses in ITP and iTTP.<sup><xref rid="R4" ref-type="bibr">4</xref>&#8211;<xref rid="R6" ref-type="bibr">6</xref></sup> Responses often last months or longer, but relapses are not uncommon.</p><p>In ITP, regimens span 4 to 12 infusions of 16 mg/kg IV daratumumab weekly. In iTTP, 4 to 6 weekly IV doses or 1800 mg subcutaneously have been used and combination with rituximab or TPO-RA, as is the case of romiplostim or eltrombopag, is common.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> The treatment is generally well tolerated. Mild infusion reactions have been reported, with hypogammaglobulinemia being documented in several cases, as well as a risk for concomitant infections. Published are largely from case reports and retrospective series, with no controlled trials, risk of bias, small sample sizes, and inconsistent regimens limit generalizability. Currently, a multicenter Phase II trial (DART, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04703621">NCT04703621</ext-link>) is ongoing in r/r ITP.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Preliminary results are promising, but more systematic data will help determine daratumumab&#8217;s future role. Considering the available data published or presented at major conferences, daratumumab should be considered in relapsed or refractory ITP or iTTP after failure of standard therapies. Mechanistic combination with rituximab or TPO-RA can enhance efficacy. Risks include cost, associated hypogammaglobulinemia and infection. Daratumumab is a mechanistically rational option for relapsed or refractory immune platelet disorders. Though evidence remains limited, its ability to deplete LLPCs makes it a promising salvage therapy, but large international controlled trials are needed.</p><sec><title>ACKNOWLEDGMENTS</title><p>C.T. is funded by a national grant of the Romanian Research Ministry&#8212;PNRR 1089 2024-2026 (PNRR/2022/C9/MCID/18, Contract No. 760278/26.03.2024), by an international grant of the European Commission&#8212;Horizon Europe Framework Network, HORIZON-TMA-MSCA-DN (Proposal Number 101227725&#8212;&#8220;Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival&#8212;ACHILLES&#8221;), by a bilateral collaboration grant between Romania and Moldova (PN-IV-P8-8.3-ROMD-2023-0036).</p></sec><sec><title>AUTHOR CONTRIBUTIONS</title><p>C.T. wrote the manuscript. R.P.G. supervised and corrected the work.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Conflict of interest: The authors declare that they have no conflict of interest.</p></fn><fn fn-type="financial-disclosure"><p>C.T. is funded by a national grant of the Romanian Research Ministry&#8212;PNRR 1089 2024-2026 (PNRR/2022/C9/MCID/18, Contract No. 760278/26.03.2024), by an international grant of the European Commission&#8212;Horizon Europe Framework Network, HORIZON-TMA-MSCA-DN (Proposal Number 101227725&#8212;&#8220;Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival&#8212;ACHILLES&#8221;), by a bilateral collaboration grant between Romania and Moldova (PN-IV-P8-8.3-ROMD-2023-0036).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crickx</surname><given-names>E</given-names></name><name name-style="western"><surname>Audia</surname><given-names>S</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia.</article-title><source>Haematologica</source><year>2021</year>;<volume>106</volume>(<issue>12</issue>):<fpage>3198</fpage>&#8211;<lpage>3201</lpage>.<pub-id pub-id-type="pmid">34348453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2021.279232</pub-id><pub-id pub-id-type="pmcid">PMC8634173</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Str&#252;&#223;mann</surname><given-names>T</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab.</article-title><source>Ann Hematol</source><year>2023</year>;<volume>102</volume>(<issue>1</issue>):<fpage>245</fpage>&#8211;<lpage>247</lpage>.<pub-id pub-id-type="pmid">36394581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00277-022-05035-y</pub-id><pub-id pub-id-type="pmcid">PMC9807464</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neunert</surname><given-names>CE</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DM</given-names></name><name name-style="western"><surname>Grace</surname><given-names>RF</given-names></name><name name-style="western"><surname>Kuhne</surname><given-names>T</given-names></name><name name-style="western"><surname>McCrae</surname><given-names>KR</given-names></name><name name-style="western"><surname>Terrell</surname><given-names>DR</given-names></name></person-group>. <article-title>The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia.</article-title><source>Blood Adv</source><year>2024</year>;<volume>8</volume>(<issue>13</issue>):<fpage>3578</fpage>&#8211;<lpage>3582</lpage>.<pub-id pub-id-type="pmid">38608258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/bloodadvances.2023012541</pub-id><pub-id pub-id-type="pmcid">PMC11319830</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoubi</surname><given-names>I</given-names></name><name name-style="western"><surname>Warwar</surname><given-names>A</given-names></name><name name-style="western"><surname>Parek</surname><given-names>S</given-names></name><name name-style="western"><surname>Preis</surname><given-names>M</given-names></name></person-group>. <article-title>Daratumumab and romiplostim combined therapy for a long-standing refractory primary immune thrombocytopenia&#8212;case report.</article-title><source>Immunotargets Ther</source><year>2025</year>;<volume>14</volume>:<fpage>1</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">39802214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/ITT.S487895</pub-id><pub-id pub-id-type="pmcid">PMC11721704</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>RP</given-names></name></person-group>. <article-title>Daratumumab in children with advanced idiopathic thrombocytopenic purpura.</article-title><source>Blood Sci</source><year>2025</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e00245</fpage>.<pub-id pub-id-type="pmid">40678406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/BS9.0000000000000245</pub-id><pub-id pub-id-type="pmcid">PMC12269808</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>Daratumumab in relapsed or refractory pediatric immune thrombocytopenia.</article-title><source>N Engl J Med</source><year>2025</year>;<volume>392</volume>(<issue>20</issue>):<fpage>2069</fpage>&#8211;<lpage>2071</lpage>.<pub-id pub-id-type="pmid">40435473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2501527</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales-Lopez</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Provan</surname><given-names>D</given-names></name></person-group>. <article-title>The new era of primary immune thrombocytopenia management in adults: a narrative review of current and emerging treatments.</article-title><source>Blood Rev</source><year>2025</year>;<volume>9</volume>:<fpage>101300</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.blre.2025.101300</pub-id><pub-id pub-id-type="pmid">40374446</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="webpage"><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/study/NCT04703621" ext-link-type="uri">https://www.clinicaltrials.gov/study/NCT04703621</ext-link>. Accessed July 24, 2025.</comment></mixed-citation></ref></ref-list></back></article></pmc-articleset>